Enhancing Drug Delivery with Supramolecular Amphiphilic Macrocycle Nanoparticles: Selective Targeting of CDK4/6 Inhibitor Palbociclib to Melanoma

Attia, M. F.; Ogunnaike, E. A.; Pitz, M.; Elbaz, N. M.; Panda, D. K.; Alexander-Bryant, A.; Saha, S.; Whitehead, D. C.; Kabanov, A.

doi:10.1101/2023.11.21.567974

bioRxiv · 10.1101/2023.11.21.567974

Enhancing Drug Delivery with Supramolecular Amphiphilic Macrocycle Nanoparticles: Selective Targeting of CDK4/6 Inhibitor Palbociclib to Melanoma

Attia, M. F.·Ogunnaike, E. A.·Pitz, M.·Elbaz, N. M.·Panda, D. K.·Alexander-Bryant, A.·Saha, S.·Whitehead, D. C.·Kabanov, A.

View original source ↗Export metadata ↓

Abstract

Drug delivery systems based on amphiphilic supramolecular macrocycles have garnered increased attention over the past two decades due to their ability to successfully formulate nanoparticles. Macrocyclic (MC) materials can self-assemble at lower concentrations without the need for surfactants and polymers, but surfactants are required to form and stabilize nanoparticles at higher concentrations. Using MCs to deliver both hydrophilic and hydrophobic guest molecules is advantageous. We developed two novel types of amphiphilic macrocycle nanoparticles (MC NPs) capable of delivering either Nile Red (NR) (a hydrophobic model) or Rhodamine B (RhB) (a hydrophilic model) fluorescent dyes. We extensively characterized the materials using various techniques to determine size, morphology, stability, hemolysis, fluorescence, loading efficiency (LE), and loading capacity (LC). We then loaded the CDK4/6 inhibitor Palbociclib (Palb) into both MC NPs using a solvent diffusion method. This yielded Palb-MC NPs in the size range of 65-90 nm. They exhibited high stability over time and in fetal bovine serum with negligible toxicity against erythrocytes. Cytotoxicity was minimal when tested against RAW macrophages, human fibroblast HDFn, and adipose stromal cells (ASCs) at higher concentrations of MC NPs. Cell viability studies were conducted with different concentrations of MC NPs, Palb-MC NPs, and free Palb against RAW macrophages, human U-87 GBM, and human M14 melanoma cell lines in vitro. Flow cytometry experiments revealed that blank MC NPs and Palb-MC NPs were selectively targeted to melanoma cells, resulting in cell death compared to the other two cell lines. Future work will focus on studying the biological effect of MC NPs including their binding affinity with molecules/receptors expressed on the M14 and other melanoma cell surface by molecular docking simulations. Subsequently, we will evaluate the MCs as a component of combination therapy in a murine melanoma model. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=154 SRC="FIGDIR/small/567974v1_ufig1.gif" ALT="Figure 1"> View larger version (39K): org.highwire.dtl.DTLVardef@5cddb9org.highwire.dtl.DTLVardef@e0c4e0org.highwire.dtl.DTLVardef@9d6838org.highwire.dtl.DTLVardef@2556b2_HPS_FORMAT_FIGEXP M_FIG C_FIG

Source connections

Published article ↗

Explore related subjects

pharmacology and toxicology Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Attia, M. F., Ogunnaike, E. A., Pitz, M., Elbaz, N. M., Panda, D. K., Alexander-Bryant, A., Saha, S., Whitehead, D. C., Kabanov, A.. 2023-11-21. Enhancing Drug Delivery with Supramolecular Amphiphilic Macrocycle Nanoparticles: Selective Targeting of CDK4/6 Inhibitor Palbociclib to Melanoma. https://doi.org/10.1101/2023.11.21.567974

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

A metastable GαS/β-arrestin complex sustains endosomal PTH1R signaling

G protein-coupled receptors (GPCRs) initiate cellular signaling by activating heterotrimeric G proteins at the plasma membrane and are silenced when beta-arrestin binds the phosphorylated receptor, preventing G protein binding. However, many receptors continue to generate cAMP after internalization, even while barr is bound, a paradox that lacked a molecular mechanism in live cells. A direct barrestin1-Gas interface in the PTH1R-barr1-Gas complex has recently been defined structurally, but whether the complex operates in endosomes, and how it behaves there, has not been established. Using intact cells, we examine the assembly at three spatial resolutions. Confocal imaging with a nanobody selective for nucleotide-free Gas places activated Gas, barr, and agonist-occupied PTH1R on the same endosomes. Single-molecule localization microscopy, with illumination modes that separate the plasma membrane from the endosomal membrane in single cells, shows that the agonist recruits Gas and barr at both membranes. FRET, however, reveals a specific interaction only on endosomes, where a Gas inhibitor restricted to that compartment abolishes the sustained cAMP phase without affecting receptor internalization. Weighted-ensemble-enhanced molecular simulations show that the complex is metastable, releasing Gas through a large rigid-body rotation away from barr while barr itself tightens its interactions with the receptor. These findings provide a molecular basis for endosomal Gs/cAMP signaling and open a new avenue for drug development targeting this pathway.

pharmacology and toxicology↗

bioRxiv2026

Advancing AOPs for genotoxicity through quantifying KERs linking DNA alkylation to increase in mutations and chromosome aberrations

Quantitative Adverse Outcome Pathways (qAOPs) help translate mechanistic knowledge into quantitative toxicity predictions; however, their development is constrained by the limited availability and heterogeneity of quantitative data. Here, we investigated the feasibility of developing a qAOP for genotoxicity by modeling quantitative relationships linking DNA alkylation to increased mutations and structural chromosome aberrations through intermediate biological key events (KEs). We compiled and harmonized published concentration-response data from human lymphoblastoid TK6 cells exposed to ethyl methanesulfonate, methyl methanesulfonate, or N-ethyl-N-nitrosourea, covering eight genotoxicity assays representing five KEs with well-established dependencies. We evaluated sources of variability, compared points of departure (PoDs), and quantified relationships between successive events using response-response modeling. Substantial between-study variability could to a limited extent be explained through differences in experimental design while batch effects for individual studies and researchers were substantial. PoD estimates that were calculated from combined results of independent studies with similar experimental design, were often uncertain due to insufficient concentration-response characterization or conflicting results between studies. Nevertheless, response-response modeling suggested a threshold effect for certain key-event relationships (KERs). Specifically, DNA adducts seemed to be triggered at lower concentrations of alkylating agents compared to the subsequent KEs of DNA strand breaks and chromosome aberrations. Furthermore, these fitted response-response models can be used for prediction of downstream KEs from earlier ones. The general approach we developed for BMC analysis followed by response-response modeling is applicable to other AOPs as well. These findings highlight both the feasibility and limitations of using existing data for qAOP development.

pharmacology and toxicology↗

bioRxiv2026

Deoxycholic Acid (DCA) a Secondary Bile Acid, Mitigates Ovariectomy-Induced Bone Loss and promotes Bone Healing: A Novel Candidate for Orthopaedic Applications

Introduction Postmenopausal osteoporosis (PMO) is a metabolic disorder, characterized by accelerated bone loss, gut microbiota (GM) dysbiosis and altered microbial metabolites. Deoxycholic acid (DCA) is a secondary bile acid with an FDA-approved drug status for submental fat treatment in adults; however its effect on bone health remains underexplored. Materials and Methods This study investigated the effects of DCA on bone health using both preclinical animal model of PMO and clinical samples from PMO women. DCA (20 mg/kg) was administered to ovariectomised (OVX) mice for 45 days, and its effects on bone microarchitecture and serum cytokines were analysed. Osteoclastogenesis and osteoblastogenesis were evaluated using murine and human samples. Untargeted and targeted metabolomics analyses were performed using an ultra-high-performance liquid chromatographic system coupled with high-resolution Orbitrap mass spectrometry (HRMS). Secondary analysis of 16S rRNA sequencing data was performed using R programming. Results GM analysis and plasma metabolomics revealed an alteration in bacterial taxa associated with secondary BA synthesis and reduced circulating DCA levels. DCA administration improved impaired trabecular and cortical bone microarchitecture in the OVX mice by inhibiting osteoclastogenesis and enhancing osteoblastogenesis. Moreover, DCA altered circulating osteoclastogenic (IL-6, Il-9, IL-17A, IFN-{gamma}, RANKL) and osteoblastogenic (OPG, TGF-{beta}, IL-10) factors. Mechanically, DCA suppressed osteoclast differentiation and the expression of genes associated with osteoclast formation (NFATC1, NFKB, TRAF6, TREM2, SYNB), fusion (CSF1R, DC-STAMP, CD47), and resorption (CTSK, ATP6VOD1, ATP6VOD2, CAR2, SPP1) in human peripheral blood mononuclear cells (PBMCs), while promoting osteogenic differentiation and matrix mineralization in bone marrow-derived mesenchymal stem cells (BMSCs) from PMO women. Additionally, DCA enhanced the nascent calcium deposition at the fracture site and improved bone healing via inhibiting osteoclastogenesis. Conclusion Overall, reduced DCA availability was associated with PMO, while DCA treatment mitigated OVX-induced bone loss and improved bone healing. This study highlights the therapeutic potential of DCA for maintaining both bone homeostasis in PMO and fracture healing with immense orthopaedic applications.

pharmacology and toxicology↗